9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 40Age Group: 18 Years to 85 Years   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: MPM phase II Carbo/VNBStudy First Received: January 3, 2006Last Updated: September 17, 2009Estimated Primary Completion Date: September 2009Primary Outcome Measures:Response|Survival|FeasibilitySponsors and Collaborators:Rigshospitalet, DenmarkResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00272558...

Continue reading

Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

ConditionMalignant (Pleural) MesotheliomaEstimated Enrollment: 10Age Group: Child, Adult, SeniorGender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NL24050.000.08Study First Received: June 1, 2010Last Updated: February 26, 2014Estimated Primary Completion Date: October 2011Primary Outcome Measures:number of cytotoxic T cells and regulatory T cells in the blood of patients|safety and toxicitySponsors and Collaborators:Erasmus Medical CenterResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01241682...

Continue reading

Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed

ConditionMalignant MesotheliomaEstimated Enrollment: 25Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: EORTC-08992Study First Received: January 28, 2000Last Updated: July 17, 2012Estimated Primary Completion Date: June 2001Primary Outcome Measures:Sponsors and Collaborators:European Organisation for Research and Treatment of Cancer - EORTCResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00004254...

Continue reading

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 69Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCCTG-N0021|CDR0000068659Study First Received: June 6, 2001Last Updated: December 5, 2016Estimated Primary Completion Date: August 2004Primary Outcome Measures:time to progression|survival|quality of lifeSponsors and Collaborators:Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00017186...

Continue reading

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 141Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: TreatmentStudy ID Numbers: 07-091Study First Received: December 10, 2007Last Updated: January 19, 2017Estimated Primary Completion Date: November 2011Primary Outcome Measures:To establish the maximally tolerated dose (MTD) of intraoperative Intrathoracic/Intraperitoneal hyperthermic gemcitabine and cisplatin combination modulated by amifostine and sodium thiosulfate in patients with malignant pleural mesothelioma.|To determine and quantitate the safety of this combination in these patients by defining the dose limiting toxicity.|To study the pharmacokinetics of gemcitabine and cisplatin combination administered in...

Continue reading

Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura

ConditionMalignant MesotheliomaEstimated Enrollment: 256Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Primary Purpose: TreatmentStudy ID Numbers: EORTC-08983Study First Received: March 7, 2000Last Updated: July 17, 2012Estimated Primary Completion Date: January 2003Primary Outcome Measures:Sponsors and Collaborators:European Organisation for Research and Treatment of Cancer - EORTCResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00004920...

Continue reading

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 840Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Primary Purpose: TreatmentStudy ID Numbers: BTS-MRC-MS01|CDR0000347461|ISRCTN54469112|EU-20349Study First Received: January 9, 2004Last Updated: August 6, 2013Estimated Primary Completion Date: nullPrimary Outcome Measures:Overall survival|Palliation of chest pain, breathlessness, malaise (e.g., feeling weak, tiredness, anorexia), and sweating attacks|Performance status as measured by WHO grade|Analgesic usage|Toxicity as measured by the NCIC CTC|Quality of life as assessed by the European Organization for Research and Treatment of Cancer|Tumor response as measured by the RECIST criteria|Progression-free survival as measured by CT scanSponsors and Collaborators:Medical Research Council|National Cancer Institute (NCI)Result...

Continue reading

Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 6Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000066157|P30CA006927|FCCC-96087|NCI-G98-1401Study First Received: November 1, 1999Last Updated: April 16, 2013Estimated Primary Completion Date: December 1999Primary Outcome Measures:Sponsors and Collaborators:Fox Chase Cancer Center|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00003263...

Continue reading

SU5416 in Treating Patients With Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 45Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCI-2012-02351|UCCRC-10409|UCCRC-NCI-44|NCI-44|CDR0000068023Study First Received: July 5, 2000Last Updated: May 31, 2013Estimated Primary Completion Date: February 2007Primary Outcome Measures:Sponsors and Collaborators:National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00006014...

Continue reading

Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery

ConditionMalignant MesotheliomaEstimated Enrollment: 60Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Primary Purpose: TreatmentStudy ID Numbers: CDR0000564058|COL-ALIMESO|INCA-RECF0441|COL-2006-04Study First Received: October 5, 2007Last Updated: May 14, 2011Estimated Primary Completion Date: May 2011Primary Outcome Measures:Individual dosage-adapted protocol|Relationship between pharmacokinetic and pharmacodynamic parameters|Pharmacokinetics|Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)Sponsors and Collaborators:Centre Oscar Lambret|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00541073...

Continue reading